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1. Introduction 
Africa is constituted of 53 independent countries (taking both South and North Sudan as one), 
has a one billion population and provides home to about 11% of the world’s population. The 
human population in Africa was projected to grow at the rate of 2.6% from the 770 million 
people in 2005 to 2 billion in 2050 (Shapley, 2008). It currently carries a huge burden of 
tuberculosis (TB), estimated at 30% of the total global number of cases in 2009, coming second 
only after Asia (50%). In the same vein, in 2009, approximately 41% (9/22) of the highest 
burdened countries (HBCs) with TB worldwide were found in Africa (WHO, 2010a). Similarly, 
the World Health Organization (WHO) in 2007 estimated that the average incidence of TB in 
African countries more than doubled between 1995 and 2005 (WHO, 2007).  
Generally, the burden of TB in Africa is driven by a generalized HIV epidemic; and the 
African region accounted for approximately 80% of the estimated 11–13% of the TB deaths 
which were HIV-positive in 2009 (WHO, 2010a). This problem is compounded by the 
general weak health care systems, inadequate laboratories, and conditions that promote 
transmission of infection, resulting in the emergence of drug-resistant Mycobacterium 
tuberculosis strains (Chaisson and Martinson, 2008). Other compounding factors, apart from 
HIV, that have resulted in the increasing trend of TB in Africa are  poverty, which is closely 
related to malnutrition, crowded living conditions, lack of access to free or affordable health 
care services, and dependence on traditional healers that can facilitate the transmission of 
tuberculosis (Parson et al., 2011). Occasional wars and civil disturbances worsen this 
situation and this is even complicated by droughts and regular natural disasters. Other self 
inflicted problems are poor government funding of health care services, occasioned by 
massive corruption and leading to diversion of meager local and foreign resources.  
Despite these gloomy outlooks, some African countries have achieved commendable 
landmarks in reversing the frightening global trend of TB. For example, Kenya and the 
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United Republic of Tanzania were among the 13 countries listed from the HBCs that 
achieved treatment success rate target of 85% set by WHO for new sputum smear-positive 
cases of pulmonary TB (WHO, 2010a). Therefore, with concerted efforts and co-ordination 
within the African continent, greater achievements can be recorded to curtail the scourge of 
TB which has inflicted so much pain in Africans. Finally, intensified efforts to reduce deaths 
among HIV/+ TB co-infected cases are needed, especially in sub-Saharan Africa. 
2. Surveillance system 
The bane of TB diagnosis in Africa has been attributed to poorly coordinated national 
tuberculosis programs (NTPs), culminating in weak health systems. As a result of this, 
individuals co-infected with TB/HIV are made to steer through the complicated, harrowing 
and weak local health systems in order to get medical care. Many shuffle between health 
clinics for TB medications and district hospitals for antiretroviral drugs in a system where TB 
and HIV treatment and care are disjointed and therefore disintegrated.  While services and 
drugs are generally free or highly subsidized, patients still complain about the cost of 
laboratory examinations, hospitalization, and transportation. This arises because patients still 
have to pay for several other services like X-ray and hospitalization which are really 
exorbitantly expensive and out of reach for some of the patients. Since most patients have to 
visit clinics far from their homes, the cost of transportation is often unbearable and the distress 
of travel further discourages them. Furthermore, TB control relies on passive case finding 
among individuals self-presenting to health care facilities, followed by either diagnosis based 
on clinical symptoms or laboratory diagnosis using insensitive sputum smear microscopy. 
Since repeated visits have to be made because presentations of serial sputum specimens are 
required (one taken on the spot and the second brought in the following morning), there are 
generally high default rates due to cost of visits and logistics. As a result of the bottlenecks 
encountered, patients are reluctant to visit these health facilities, therefore resulting in poor 
case finding and ability to achieve effective diagnosis and accurate treatment.  
Health seeking behavior and non-adherence to therapy has been cited as a major barrier to the 
control of TB control globally (Gopi et al., 2007).   There are reports from Nigeria and other 
developing countries that delay in TB diagnosis and treatment initiation is common (Salami 
and Oluboyo, 2002; Gopi et al., 2007; Odusanya and Babafemi, 2004), and this has been 
ascribed to negligence’s from both the patients and doctors. Delay in diagnosis may aggravate 
the disease, augment the risk of death and enhance person to person transmission in the 
community (Odusanya and Babafemi, 2004).  In Tanzania, 15% of patients were found to 
report to a health facility within 30 days of the onset of symptoms (Wandwalo and Morkve, 
2000)  while studies from Nigeria reported 81% (Enwuru et al., 2002) and 83% (Odusanya and 
Babafemi, 2004)   patients delay for more than one month. Reasons for this are patients visiting 
local and poorly equipped private medical facilities, chemists, prayer houses and traditional 
healers; coupled with these, are poor knowledge and awareness about the disease among 
Africans in general (Odusanya and Babafemi, 2004; Enwuru et al., 2007; Okeibunor et al., 2007). 
3. Infrastructural facilities and laboratory services 
“Lack of new diagnostic tools and inadequate laboratory capacity hinders timely detection 
and management of drug resistance, with catastrophic consequences when dealing with 
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lethal forms of TB”, says Bert Voetberg, a lead health specialist in the World Bank’s Africa 
region. In most African countries, smear microscopy laboratories consist of single rooms and 
are understaffed. In addition, they generally possess poorly maintained microscopes, and 
some of these laboratories lack consistent sources of electricity and clean water (Parsons et 
al., 2011). Thus, the critical factor in TB control regarding early diagnosis and treatment that 
should limit the spread of the disease and reduce mortality is still an enormous problem in 
Africa. According to Chaisson and Martinson (2008), throughout Africa, the vast majority of 
the diagnosis of TB rests on the microscopic detection of acid-fast bacilli in sputum; an 
insensitive technique that is particularly ill suited for the detection of TB in HIV-infected 
patients, who have fewer bacilli in their sputum and more frequently suffer from extra-
pulmonary TB than HIV negative patients. In patients with active pulmonary TB, only an 
estimated 45% of infections are detected by sputum microscopy when compared to culture 
(Dye et al., 2005). This test, first developed in the 1880s and basically unchanged today, has 
the advantage of being simple, but has very low sensitivity (especially among HIV-
coinfected patients). It is also very dependent on the skills of the technician, and a single 
technician can only process a relatively small number of slides per day (Perkins et al., 2006). 
In addition, this method cannot differentiate between drug-sensitive and drug resistant TB, 
nontuberculous mycobacteria, and other Ziehl-Neelsen positive micro-organisms like 
Nocardia and Rhodocossus species. Due to these limitations, a staggering three million 
people who present annually with suspected TB may not be properly and timely diagnosed, 
because their infection (so-called smear-negative disease) cannot be detected by sputum 
microscopy (Onyebujoh et al., 2006). Moreover, a significant over and misdiagnosis is 
expected because a part of the ZN positives do not represent tuberculosis. Therefore, the 
timely introduction of the use of light-emitting diode (LED) fluorescence microscopes (FM) 
will go a long way in improving the shortcomings of the conventional smear diagnosis of TB 
(Cuevas et al., 2011; Hung et al., 2007). "The fact that LED microscopes are more affordable 
than conventional fluorescent microscopes, and can be powered by battery in some cases, 
makes fluorescent microscopy potentially more widely available, and this should result in a 
better diagnostic for TB," said lead author Dr. Andrew Whitelaw from the University of 
Cape Town based on a study carried out in South Africa. It is also believed that other high 
HIV and TB burden countries in Africa would benefit a lot from the LED microscopy. 
Again, laboratories with the capacity to provide culture and (molecular) drug sensitivity test 
(DST) services are essential for the diagnosis of drug-resistant TB; culture services are also 
important for diagnosis of smear negative TB, especially in African countries where the 
prevalence of HIV is high. However, capacity to perform culture and DST is seriously limited 
in African countries (WHO, 2009). Since the standard of care for TB diagnosis recommended 
by WHO (2010a) is (i) sputum smear microscopy for all cases and (ii) expansion of the use of 
culture to diagnose all bacteriologically-positive (not just smear-positive) cases towards the 
ultimate goal of using culture (or equivalents such as molecular tests) in the diagnosis of all 
cases, it becomes obvious that most countries in Africa will never achieve this goal because of 
the serious deficits in both human and infrastructural capacities. This is apparent especially 
when the demands for a biosafety level 3 facility for culture of M. tuberculosis (MTB) is 
introduced which is out of reach in almost all settings. Currently, very few countries in Africa 
can effectively carry out culture to confirm cases of TB. As a result of limitation in 
Mycobacterium culture capability, barely 5% countries in Africa can independently carry out 
drug susceptibility testing for infected TB patients (Table 1). Consequently, accurate diagnosis 
for effective treatment of TB patients is heavily compromised.  
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Countries Population
(Million) 
Burden of TB 
incidence 
(no. of cases 
/100,000 
individuals/
yr) 
% of TB 
patients 
that are 
HIV 
positive 
(%) 
Mortality 
due to 
TB/100,0
00 popu-
lation 
Smear 
micro-
scopy 
labora-
tories per 
100,000 
popu-
lation 
Culture 
labs 
per 5 
million 
popu-
lation 
Drug 
susce-
ptibility 
test (DST) 
labs/ 10 
million 
popu-
lation 
Second 
line DST 
Available 
Local TB 
Funding 
National 
Reference 
TB 
Laboratory 
Algeria 35 59 NA 2.4 0.7 3.7 0.9 In country Poor Yes 
Angola 18 298  15 30 0.8 0.3 0.5 No Fair Yes 
Benin 9 93 16 17 0.6 0.6 0.6 In country Poor Yes 
Botswana 2 694 66 57 2.3 2.6 5.1 Outside Poor Yes 
Burkina 
Faso 
16 215 20 55 0.7 0 0 Outside Poor Yes 
Burundi 8 348 46 77 2.0 0.6 0 No Poor Yes 
Cameroon 20 182 40 17 NA NA NA In and 
outside 
Poor Yes 
Cape Verde <1 148 20 27 3.2 0 0 Outside Poor Yes 
Central 
African 
Republic 
4 327 33 44 1.6 1.1 2.3 No Very 
poor 
Yes 
Chad 11 283 - 63 0.5 0 0 No Very 
poor 
Yes 
Comoros <1 39 - 7.8 NA NA NA No Very 
poor 
Yes 
Congo,* 
Democratic 
Republic 
(DRC) 
66 372 20 76 2.2 <0.1 0.2 No  Poor Yes 
Congo, 
Republic 
4 382 48 43 0.7 0 0 Outside Very 
poor 
Yes 
Cote 
d’Ivoire 
21 399  30 85 0.5 0.2 0.5 No Poor Yes 
Djiboutu <1 620 10 77 1.9 5.8 0 Outside Very 
poor 
Yes 
Egypt 83 19 0 1.1 0.3 1.1 0.1 In country Fair/ 
Good 
Yes 
Equitorial 
Guinea 
<1 117  17 5 4.3 0 0 No  Very 
Good 
No 
Eritrea 5 99  - 14 1.5 1.0 2.0 Outside Poor Yes 
Ethiopia* 83 359  20 64 1.4 0.1 0.2 Outside Good Yes 
Gabon 1 501 59 62 0.9 3.4 6.8 Outside Poor No 
Gambia, The 2 269  16 48 1.9 2.9 5.9 No Poor Yes 
Ghana 24 201  22 46 1.0 0.6 0.8 No Fair Yes 
Guinea 10 3 24 72 0.5 0.5 1.0 In country Poor Yes 
Guinea-
Bissau 
2 229  - 30 3.3 NA NA No Poor Yes 
Kenya* 40 305  44 15 3.0 0.8 1.0 Outside Poor Yes 
Lesotho 2 634  77 14 (9.5) 0.9 2.4 4.8 Outside NA No 
Liberia 4 28 1 59 3.7 0 0 In country Poor No 
Libya 6 40  15 4.1 0.4 2.3 3.1 No Poor Yes 
Madagascar 20 261  - 57 1.3 0.3 0.5 In country Poor Yes 
Malawi 15 304  64 25 1.3 0.7 0.7 Outside Poor Yes 
Mali 13 324  16 88 0.6 0.8 1.5 Outside  Poor Yes 
Mauritania 3 330  12 90 2.2 1.5 3.0 No  Poor Yes 
Mauritius 1 22  6 <1 NA NA NA Outside NA Yes 
Morocco 32 92  NA 5.8 0.5 2.2 0.6 Outside Poor Yes 
Mozam-
bique* 
23 409  66 38  1.9 0.2 0.4 Outside Poor Yes 
Namibia 2 727  58 31 1.4 2.3 4.6 Outside 
country 
Good Yes 
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Countries Population
(Million) 
Burden of TB 
incidence 
(no. of cases 
/100,000 
individuals/
yr) 
% of TB 
patients 
that are 
HIV 
positive 
(%) 
Mortality 
due to 
TB/100,0
00 popu-
lation 
Smear 
micro-
scopy 
labora-
tories per 
100,000 
popu-
lation 
Culture 
labs 
per 5 
million 
popu-
lation 
Drug 
susce-
ptibility 
test (DST) 
labs/ 10 
million 
popu-
lation 
Second 
line DST 
Available 
Local TB 
Funding 
National 
Reference 
TB 
Laboratory 
Niger 15 181 12 41 0.3 0 0 Outside 
country 
Very 
poor 
No 
Nigeria* 155 295  26 73  0.7 0.1 0.2  Outside 
country 
Fair Yes 
Rwanda 10 376  34 76 1.9 0.5 1.0 No Poor Yes 
Sao Tome & 
Principe 
<1 98  13 19 1.2 0 0 No Poor Yes 
Senegal 13 282  7 72 0.7 1.2 2.4 In country Poor Yes 
Seychelles <1 31  - 2.6 NA NA NA In  and 
outside 
Poor No 
Sierra Leone 6 644  11 158 2.0 NA NA No Very 
poor 
Yes 
Somalia 9 285  NA 58 0.6 0 0 Non Very 
poor 
No 
South 
Africa* 
50 971  58 45  0.5 1.6 3.2 In and 
outside 
country 
Excellent Yes 
Sudan 42 119  4 24 0.9 0.1 0.2 Non Poor Yes 
Swaziland 1 1257  13 64  NA NA NA Outside 
country 
Good Yes 
Tanzania* 44 183  37 9  1.6 0.1 0.2 Outside 
country 
Poor Yes 
Togo 7 446  25 113 1.7 0.8 1.5 Non Very 
poor 
Yes 
Tunisia 10 24  2 1.8 0.6 3.4 4.9 In country Excellent Yes 
Uganda* 33 293  54 29 2.5 0.9 1.2 In country Poor Yes 
Zambia 13 433  67 27  1.7 NA 2.3 Non Poor Yes 
Zimbabwe* 13 742  78 82  1.0 0.4 0.8 Non Poor Yes 
*African countries listed among the 22 high TB burdened nations in the world 
Table 1. Showing the burden and challenges of TB in African countries 
To respond to the urgent need for simple and rapid diagnostic tools at the point of treatment 
in HBCs, the Xpert MTB/RIF assay (GeneXpert, Cephied), a rapid molecular test for TB and 
rifampicin (RIF) resistance was recently developed. Though relatively new, this molecular 
assay has been described as one of the most promising in routine diagnosis in developing 
countries owing to its high sensitivity (98.2%), specificity (99.2%) and short turn-around time 
(2 hours) (Van Rie et al., 2010). With regards to the detection of RIF resistance, the assay was 
reported to be highly sensitive (≥97.6%) and specific (≥98.1%), with performance characteristics 
which are superior to drug susceptibility testing by conventional culture-based assays and line 
probe assays (Boehme et al., 2010). The rapid detection of MTB in sputum and RIF- resistance 
allows the physician to make critical patient management decisions regarding therapy during 
the same medical encounter. As conventional sputum smear microscopy has limited 
sensitivity and culture takes at least 4–6 weeks to produce result, the Xpert MTB/RIF assay 
seems a major improvement in African countries where proper facilities are scarce and rates of 
loss to follow-up are high. The additional advantage of the Xpert MTB/RIF assay is that when 
performed correctly, it is not associated with a measurable infection risk and results in a lower 
biohazard compared with conventional smear microscopy, making the assay suitable for 
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point-of-care (POC) use in the typical African setting where bio-containment facilities are not 
readily available (Banada et al., 2010). 
4. Co-morbidities of TB and HIV/AIDS 
Globally, an estimated 11-13% of the newly diagnosed TB patients are HIV positive and 
approximately 80% of these cases are in Africa (WHO, 2010a). The HIV infection is an 
established epidemiological factor causing additional challenges to the diagnosis of TB; hence, 
a major contributor to the increased incidence of TB across the world. Infection with HIV-1 
increases the risk of reactivating latent TB infection by 80- to 100-fold, and HIV patients who 
acquire new TB infections also have higher rates of disease progression (Parson et al., 2011). 
Tuberculosis can occur at all points in the immunosuppressive spectrum of HIV disease, with 
variable presentations, and, particularly in African countries, where TB is always a major 
indicator of HIV. Multiple studies have shown that fatality rates are higher for HIV-TB-co-
infected patients who are on anti-TB treatment but not antiretroviral therapy (16 to 35%) than 
for treated TB patients who are HIV negative (4 to 9%) (Mukardi et al., 2001). The study carried 
out by Ackah et al, (1995), in Abidjan, Coˆte d’Ivoire, indicated that the highest death rates 
occurred in co-infected patients with the lowest CD4 cell counts. This is the same picture in 
most areas in Africa where HIV is prevalent. Unfortunately, despite the scale up of TB 
treatment in South Africa, the epidemic of HIV in that country has grievously compromised 
TB care and control. This scenario has manifested in increased incidence of multidrug 
resistance TB (MDR-TB) and extensively drug-resistant TB (XDR-TB). The sequel of all these 
compounding scenarios is a situation in which TB and HIV synergistically potentiates each 
other in the affected patients leading to difficulties in the accurate diagnosis of TB and 
eventually in increased rate of mortalities in the region.  
Notwithstanding the huge funds expended to fight AIDS, TB and Malaria by the Global 
Fund and PEPFAR in Africa, the bulk of these funds have been spent on AIDS, therefore 
leaving a huge deficit in the area of TB. Consequently, most attention in the past was 
diverted at building both human and infrastructural capacities for AIDS prevention; while 
that for TB was scarcely given the needed support. This has led to limited diagnostic 
capacity for TB despite the prompt diagnosis of HIV in some cases; hence, leading to most 
patients dying of TB. Therefore, the parlance “living with HIV, dying of TB” has become a 
recurrent decimal in most African countries where TB and HIV are endemic (Parson et al., 
2011; Dorman and Chaisson, 2007; Gandhi et al., 2006).  
5. Newer diagnostics 
In the face of various diagnostic challenges of TB due to compounding factors like poverty, 
HIV/AIDS and lately, the MDR-TB and XDR-TB infections in some African countries like 
South Africa, an urgent need has arisen for newer technologies to facilitate prompt 
diagnosis of TB. Clinical management of TB in African countries is hampered by the lack of 
rapid, simple and effective diagnostic tests. Correct diagnosis of TB is needed to improve 
treatment, reduce transmission, and control development of drug resistance.  
6. Public-private collaborations 
The internationally recommended DOTS strategy has been successfully implemented in the 
public sector by many National Tuberculosis Programs (NTPs), but in the private sector the 
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quality of care is generally very poor (Uplekar and Rangan, 1993; Uplekar et al., 1998). Since 
the situation of the NTPs in Africa is far from perfect, the problem has been further 
complicated by the poor operation of the DOTS program in the expanding private sector 
that is supposed to be a major TB care provider.  Resulting from the weak link between the 
public and private practitioners in terms of complementary activities, funding and 
operational researches, several TB programs that are of immense benefits to the patients are 
denied. This is particularly worrisome in the area of TB diagnosis were limited facilities are 
available for patient care. Because of the very weak interactions, only few private 
practitioners in the urban settings provide quality diagnostic services that can support 
patient care. Moreover, only few of these private care givers are accessible to foreign 
agencies that can support in the scale up TB diagnosis. The resultant effect of this is a huge 
gap in TB diagnosis and therefore increased burden of the disease especially among rural 
dwellers that rely mostly on traditional healers who are not normally integrated into 
healthcare systems by government establishments. Obviously, these practitioners usually do 
not work according to the national guidelines for the treatment of TB.  
Since traditional practices are common place in Africa and majority of Africans still live in 
rural settings with low literacy rate, many patients patronize local herbalists and quacks 
who pretend to be physicians and health givers. Traditionally, since herbal centers are not as 
expensive as most government health clinics, they are the first point of call for patients. 
Here, local herbs and other ritual concoctions are given, which in some cases worsen the 
patients health and this could be on for several weeks to years. Sadly, some of these patients 
die and some infect their relatives before recourse to government clinics/hospitals when 
complications would have set in. However, recent findings in the area of ethno-medicine 
have shown that some of the herbal medications have promising anti-tuberculosis activities. 
A lot therefore needs to be done by government and private research agencies to look into 
these assertions and see how traditional health care providers can be integrated into 
supporting TB care in rural settings in Africa.  
Both formal and informal private practitioners comprise the health sector, working on 
voluntary basis or for profit. The number of professional societies, private hospitals, 
corporate health providers as well as community and traditional healing homes is fast 
growing. Therefore, mechanisms for collaboration between the public and private health 
sectors should be established. In order to promote compliance with treatment guidelines, 
private care providers should be involved in their development, or checks on the adherence 
to treatment and cure should be organized by the public sector. They should also be 
empowered to facilitate training within the sector. Improved program coverage, patient 
access to diagnostic and treatment services, increased case detection and treatment 
outcomes, and improved overall quality of care are some of the potential benefits of 
involving private health providers in delivery of services (Uplekar and Shepards, 1991; 
Pathania et al., 1997). A model of successful public-private sector collaboration in TB control 
that is commendable in Africa is exemplified by the activities of the Damien Foundation, 
Belgium, a voluntary non-profit private TB support agency in Nigeria. This collaboration 
has over the years led to the achievement of about 85% TB active case finding and 
establishment of the first MDR-TB treatment Center in Nigeria. Though such other agencies 
abound in other African countries, however, more demonstrable milestones in terms of TB 
control coverage has to be set and seen to be achieved to justify the huge money said to be 
expended by these agencies in Africa. 
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7. Funding of TB control programs 
With the gross domestic product (GDP) of the entire African continent valued at $2.2 million 
(World Bank, 2011) as against that of the US which is estimated at between $14.6-14.7 trillion 
(World Bank 2011; BEA, 2011), it is obvious that the continent will be unable to effectively 
finance and take care of its huge health burden. This is more obvious since the highest 
placed economy in Africa, Egypt is rated 25 globally with GDP of $467, 000 and the lowest 
country, Sao Tome and Principe rated 177 globally with GDP of $300. With the myriad of 
diseases, wars natural disasters and massive corruption in the continent, it will be difficult 
to fund TB care and especially the diagnostic component given the huge resources required 
both in human and infrastructural capacities. From the recently released WHO 2010 TB 
report, nearly all countries in the region relied on external funding and support for its DOTS 
program (WHO, 2010a). Consequently, TB program across the continent is poorly funded; 
with only about 5-15% barely in a situation to fund their program domestically (Table 1). 
Unfortunately, due to the recent global recession seriously having its unprecedented effects 
on the economy of western nations, the budgets of most donor agencies are grossly reduced, 
leaving great deficits and reduction in TB control support in Africa.  
8. Political commitment 
Most African countries are politically unstable and bereft of governments that can provide 
long term policies to sustain the health system. Given these political challenges, and 
problems of incessant wars, it is difficult to implement and sustain successful DOTS 
programs. Of particular reference is Somalia that has been deprived of stable government 
for almost two decades; therefore, it has no political commitment that will help facilitate any 
national TB control program. This is evident from the absence of a national TB reference 
laboratory and a non-existent platform (either local or foreign) to screen for drug resistant 
TB (WHO, 2010a). Unfortunately however, due to ignorance and lack of political will, some 
African countries fail to acknowledge the burden of MDR-TB despite the overwhelming 
evidence that points at this. Fortunately though, after so much foot dragging, some 
countries in Africa have finally set up mechanisms to carry out national MDR-TB surveys in 
collaboration with Global fund, Center for Disease Control (CDC) and WHO. One of such 
countries is Nigeria, and preliminary findings from the survey conducted indicate a high 
rate of MDR-TB (unpublished personal communication). 
In other African countries with apparently stable governments, they are faced with self 
made problems like corruption, civil unrest that discourage full implementation of the TB 
control programs. Of particular importance again is the epidemic of HIV/AIDS which has 
incapacitated Africa, and leaving most governments with no option than to tackle the 
greater evil and leaving others like TB and Malaria for later days.  
Despite the challenges African governments are responsible for; it is most unfortunate that 
most have only paid lips service to tackling the problem of TB. Sadly enough, they are only 
gored on by the carrot and stick approaches of the western nations and agencies before they 
made the little commitment seen so far. It is obvious that a larger role of the African Union 
(AU) is needed to tackle the challenges of TB. In this direction, there is a need for an AU 
Blue Print on the policy, mechanism, funding and achievable milestones within a practicable 
timeframe to reduce the burden of TB comparable to rates seen in Europe and other areas of 
the world with low burden of the disease. 
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9. Operational research 
The fact that new technologies regarding TB diagnosis and control have been successful in 
western nations and regions of the world, does not necessarily translate to its success in 
Africa. In theory, biosafety level 3 laboratories are needed to conduct culture of MTB, 
however, so far such highly expensive and technically demanding facilities are very scarce 
in Africa. But also the recently developed molecular techniques that in principle do not need 
such expensive facilities are not as simple to implement in Africa as some assume. For 
example, despite the promise of the Xpert MTB/RIF assay in clinical trials, evidence has 
shown that knowledge to support the broader dissemination and implementation of those 
interventions (e.g., cost and financing of the intervention, provider training, availability of 
resources, monitoring the quality of intervention delivery) has limited the successful 
implementation of such innovations. Our previous experience has shown that substantial 
barriers have existed to limit prior attempts at implementing new technologies, such as the 
microscopic observation drug susceptibility assay (MODS) and the nitrate reductase assay 
(NRA). Accordingly, none of these techniques have been successfully integrated into the 
diagnostic algorithm for TB in Africa. Since no empirically-supported models exist to guide 
the dissemination and implementation of some of these technologies, sound operational 
feasibility projects are required before they are integrated into TB programs in Africa.  
Failure to carry out these assessments in the past, have lead to serious dire consequences in 
TB diagnosis despite huge resources that has been expended.  
In order to make adequate use of promising pilot research findings, especially translational 
researches are required in African countries before new techniques are rolled out on a large 
scale. Of great importance here are translational researches bothering on the use of stool for 
prompt diagnosis of pediatric TB (Cadmus et al., 2009), adaptation of the front loading 
smear microscopy (Ramsay et al., 2009), and the use of light emitting diode (LED) 
microscopes (Cuevas et al., 2011) to mention a few. These translational researches are 
urgently needed giving the advantages they may offer in combating TB in the continent. 
10. Role of international agencies 
International agencies have played leading roles in the prevention and control of TB in most 
African countries in the past 50 years. Therefore, most diagnostic improvements 
experienced in Africa are driven by foreign donors and expertise. For example, the United 
States Government through its President’s Emergency Plan for AIDS Relief (PEPFAR) spent 
about $307 million in 15 African countries between 2005 and 2008 for TB/HIV co-infected 
persons covering 367,000 patients (TTGHC, USA, 2009). Principally, the cost covered among 
other things routine TB screening in HIV infected people and improving laboratory 
surveillance systems in order to detect outbreaks of MDR- and XDR-TB.  However, judging 
from the enormity of the burden of TB in the continent, it is obvious that the funds from the 
US and agencies from other western nations are not sufficient; hence, more needs to be 
done. This is particularly important in the areas of massive laboratory scale up and quality 
personnel that will operate the various laboratories since all these are grossly inadequate.  
Currently, in Nigeria with the support of the PEPFAR program sponsored by the US 
government, the University of Maryland, through its Institute of Human Virology (IHV), 
center in Nigeria is supporting the Nigerian TB program in setting up a TB training school 
with a biosafety level 3 facility in northern Nigeria. The center has the capacity to carry out 
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LED fluorescence microscopy, culture and molecular techniques like the Hain assays as well 
as ancillary HIV diagnostic tests. Though similar sophisticated facilities abound in other 
African countries like Gambia, Mali, South Africa and Tanzania, they remain highly 
inadequate. Unfortunately, some of these facilities are merely for research and information 
gathering, rather than large scale use for TB control in such countries. However, since each 
program is handled by specific interest, there is limited coverage and sometimes no 
coordination even at the national level. 
In other to facilitate effective TB care in African countries, there is a need for coalition of 
foreign donors to achieve optimal TB control platform for diagnosis and treatment. A step 
towards this direction is the formation of “The Tuberculosis Coalition for Technical 
Assistance (TBCTA). The coalition is guiding TB CARE I which is a USAID five year 
cooperative agreement (2010-2015) that has been awarded to TBCTA with KNCV 
Tuberculosis Foundation of the Netherlands as the lead partner. TBCTA is a unique 
coalition of the major international organizations in TB control. The coalition includes  
American Thoracic Society (ATS), FHI 360, International Union Against Tuberculosis and 
Lung Disease (The Union), Japan Anti-Tuberculosis Association (JATA), KNCV 
Tuberculosis Foundation, Management Sciences for Health (MSH), World Health 
Organization (WHO). The aim of TB CARE is to contribute to reaching the following specific 
USAID goals in the TB CARE countries (some African countries inclusive) with significant 
investment. It aims at (1) Sustaining or exceeding 84% case detection rate and 87% treatment 
success rate; (2). Treat successfully 2. 55 million new sputum-positive TB cases; (3). Diagnose 
and treat 57,200 new cases of multi-drug resistant (MDR) TB. Finally, TB CARE focuses on 
five priority areas that are needed for TB control in Africa namely: increasing political 
commitment for DOTS; strengthening and expanding DOTS Programs; increasing public 
and private sector partnerships; strengthening TB and HIV/AIDS collaboration; improving 
human and institutional capacity. With this anticipated initiative getting fully implemented 
in Africa, it is envisaged, that there will be a major turn-around in TB care through accurate 
diagnosis and treatment of patients. 
11. Recommendations 
To optimize TB control in the African continent, major changes are needed. The local 
political engagement needs to be enforced, not only to regulate the delicate relationship 
between the weak public Health care system and the expanding private sector, but also to 
stimulate international involvement in addressing the challenges faced. If more funding 
would be available, the implementation of new approaches in the diagnosis and treatment 
of TB should be considered a scientific discipline in itself; with serious considerations given 
to the integration of new methods and technologies before they are rolled out in Africa. 
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